Antimicrobial composition oil composition, product comprising same, and preparation method for product thereof
Patent Information
- Application Number
- LAP929
- Authority / Receiving Office
- LA · LA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-04-30
- Filing Date
- 2022-02-07
- Publication Date
- 2026-03-27
AI Technical Summary
Most of the existing disinfection products are synthetic chemicals, which are inconvenient to use and potentially harmful to the human body and the environment. Although natural plant essential oils have antibacterial effects, they are highly toxic and difficult to be widely used.
A composition of multiple natural plant essential oils, including carvacrol, thymol, lemon oil, asiaminant oil, etc., is used to form an antimicrobial composition through synergistic effect, and is used to prepare products with antimicrobial properties.
It can effectively kill or inhibit a variety of microorganisms (such as new coronavirus, bacteria, and fungi), and is friendly to the human body and the environment, has low irritation, low corrosiveness, and has soothing and protective effects.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
Antimicrobial essential oil compositions, articles comprising the same, and methods for preparing the articles thereof.
[0001] Cross-reference to related applications
[0002] This application claims priority to Chinese Patent Application No. 202110482092.1, filed on April 30, 2021, entitled “Antibacterial Essential Oil Composition, Product Containing the Same, and Method of Preparation Thereof,” and Chinese Patent Application No. 202210059971.8, filed on January 19, 2022, entitled “Antibacterial Essential Oil Composition, Product Containing the Same, and Method of Preparation Thereof,” both of which are incorporated herein by reference in their entirety. Technical Field
[0003] This application generally relates to an essential oil composition, and more specifically, to a plant essential oil composition having antimicrobial properties. This application also relates to articles comprising antimicrobial essential oil compositions and methods for preparing articles comprising antimicrobial essential oil compositions. Background Technology
[0004] Many highly pathogenic microorganisms cause rapidly spreading infectious diseases. Such infectious diseases can even spread across several provinces, countries, or even the entire world in a short period of time, that is, rapidly develop into a "pandemic." For example, the 2019 coronavirus disease (COVID-19, also known as "novel coronavirus pneumonia") that began to break out at the end of 2019 has been recognized by the World Health Organization as meeting the characteristics of a "pandemic."
[0005] During the pandemic, disinfection is a crucial aspect of epidemic prevention and control. Currently, worldwide, synthetic chemical disinfectants (such as ethanol, peracetic acid, chlorine-based disinfectants, and phenolic disinfectants), ultraviolet light, and heat are commonly used to inactivate pathogenic microorganisms. For example, phenolic disinfectants were once one of the main disinfectants used in hospitals, playing a vital role in preventing and controlling the spread of infectious diseases. At high concentrations, phenols can lyse and penetrate cell walls, causing bacterial proteins to coagulate and precipitate, rapidly killing cells; at low concentrations, they can inactivate bacterial enzyme systems, leading to cell death. However, such disinfection measures are inconvenient to apply, have limited use, and pose a risk of secondary pollution to humans and the environment.
[0006] Essential oils based on natural plants have been traditionally used for treating infectious diseases and controlling epidemics for thousands of years. Phenolic essential oils, in particular, have excellent antibacterial effects. However, this category of essential oils also requires caution in practical applications due to their toxicity and potential irritation to the skin and mucous membranes. The antimicrobial activity of other plant essential oils has also been confirmed by numerous studies. These plant essential oil products, while inactivating pathogenic microorganisms, are harmless to humans, environmentally friendly, and align with the trends of green environmental protection and sustainable development.
[0007] Therefore, there is a need to provide plant essential oil products with antimicrobial activity.
[0008] We unexpectedly discovered that by using a combination of various single essential oils, along with specific antimicrobial active ingredients, we can obtain disinfection products that have good antimicrobial properties, are harmless to humans, and are environmentally friendly.
[0009] Summary of the Invention
[0010] To address the above problems, an antimicrobial essential oil composition is provided in the embodiments of this application. The components of the essential oil composition are all derived from natural plants, and the combination of these components gives the resulting essential oil composition good antimicrobial properties.
[0011] At least one embodiment of this application provides an antimicrobial essential oil composition, wherein, based on the total weight of the composition, the antimicrobial essential oil composition comprises: (1) 0.0001-80% of one or more selected from carvacrol and thymol; (2) 0.0001-99.9% of one or more selected from lemon oil, sweet orange oil, bitter orange peel oil, white lemon oil, and grapefruit peel oil; and (3) 0.0001-99.9% of peppermint oil, peppermint oil, and peppermint extract. (3) one or more of the following: oil and peppermint oil; (4) 0.0001-20% of one or more of the following: bay leaf oil and oregano oil; (5) 0.0001-20% of one or more of the following: patchouli oil, sandalwood oil and rosemary oil; (6) 0.0001-20% of one or more of the following: geranium oil, pine needle oil and cypress oil; and (7) optionally, 0.0001-20% of one or more of the following: perilla oil, chrysanthemum oil and vitex leaf oil.
[0012] In one aspect, based on the total weight of the composition, the antimicrobial essential oil composition comprises: (1) 2-80% of one or more selected from carvacrol and thymol; (2) 2-50% of one or more selected from lemon oil, sweet orange oil, bitter orange peel oil, white lemon oil and grapefruit peel oil; (3) 5-40% of one or more selected from Asian peppermint oil, Asian peppermint oil, peppermint oil and peppermint oil; (4) 2-20% of one or more selected from bay leaf oil and oregano oil; (5) 0.1-5% of one or more selected from patchouli oil, sandalwood oil and rosemary oil; (6) 2-20% of one or more selected from geranium oil, pine needle oil and cypress oil; and (7) optionally, 2-15% of one or more selected from perilla oil, chrysanthemum oil and vitex leaf oil.
[0013] On the other hand, based on the total weight of the composition, the antimicrobial essential oil composition may optionally also contain one or more selected from the group consisting of: (8) 0.0001-20% honeysuckle oil; (9) 0.0001-20% chuanxiong oil; (10) 0.0001-20% cocklebur oil; and (11) 0.0001-20% forsythia oil.
[0014] On the other hand, based on the total weight of the composition, the antimicrobial essential oil composition comprises: (1) 5% carvacrol and 5% thymol; (2) 35% lemon oil; (3) 30% peppermint oil; (4) 10% bay leaf oil; (5) 0.5% patchouli oil; (6) 5% geranium oil; and (7) 9.5% perilla oil.
[0015] On the other hand, based on the total weight of the composition, the antimicrobial essential oil composition comprises: (1) 0.005% carvacrol and 0.005% thymol; (2) 0.1% lemon oil; (3) 99.58% Asian peppermint oil; (4) 0.005% bay leaf oil; (5) 0.25% patchouli oil; (6) 0.005% geranium oil; and (7) 0.05% perilla oil.
[0016] On the other hand, based on the total weight of the composition, the antimicrobial essential oil composition comprises: (1) 0.005% carvacrol and 0.005% thymol; (2) 99.5% lemon oil; (3) 0.25% peppermint oil; (4) 0.005% bay leaf oil; (5) 0.18% patchouli oil; (6) 0.005% geranium oil; and (7) 0.05% perilla oil.
[0017] On the other hand, based on the total weight of the composition, the antimicrobial essential oil composition comprises: (1) 51.25% carvacrol; (2) 26.25% thymol; (3) 8.75% lemon oil; (4) 7.5% peppermint oil; (5) 2.5% bay leaf oil; (6) 0.125% patchouli oil; (7) 1.25% geranium oil; and (8) 2.375% perilla oil.
[0018] On the other hand, based on the total weight of the composition, the antimicrobial essential oil composition comprises: (1) 25% carvacrol and 25% thymol; (2) 2% lemon oil; (3) 10% peppermint oil; (4) 20% bay leaf oil; (5) 0.5% patchouli oil; (6) 2% geranium oil; (7) 5% honeysuckle oil; (9) 4% ligusticum oil; (10) 0.3% cocklebur oil; and (11) 0.2% forsythia oil.
[0019] In another respect, the microorganisms are selected from bacteria, fungi, viruses, mycoplasma, and combinations thereof.
[0020] In another aspect, the microorganism is one or more of the following: SARS-CoV-2, influenza virus, rhinovirus, respiratory syncytial virus, enterovirus, adenovirus, herpesvirus, Coxsackievirus, and poliovirus.
[0021] On the other hand, the microorganism in question is the novel coronavirus.
[0022] In another aspect, the microorganism is one or more of the following: Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Moraxella catarrhalis, Escherichia coli, Shigella dysenteriae, Staphylococcus albus, and Candida albicans.
[0023] In another respect, the microorganism is Mycoplasma pneumoniae.
[0024] At least one embodiment of this application also provides an article comprising an antimicrobial essential oil composition.
[0025] In one aspect, the article includes articles capable of reducing or killing microorganisms on one or more of hard surfaces, textiles, skin, mucous membranes, or hair.
[0026] On the other hand, the product is selected from one or more of the following: mask beads, sanitary wipes, air fresheners, oral sprays, hand sanitizers, shampoos, conditioners, shower gels, cosmetics, skin care products, air gels, antibacterial sprays, surface cleaners, and detergents.
[0027] On the other hand, the product is a protective item.
[0028] On the other hand, the product is selected from one or more of civilian masks, medical masks, protective gloves, and protective clothing.
[0029] On the other hand, the product in question is a beaded face mask.
[0030] On the other hand, the product is food or health product.
[0031] On the other hand, the product is selected from one or more of chewing gum, chewing pills, popping beads, gel candy, hard candy, beverages, and dietary supplements.
[0032] At least one embodiment of this application also provides a method for preparing an article comprising an antimicrobial essential oil composition, comprising: uniformly mixing all components of the antimicrobial essential oil composition to form an essential oil masterbatch, an essential oil microcapsule, or an essential oil bursting bead; and combining the essential oil masterbatch, the essential oil microcapsule, or the essential oil bursting bead with other components of the article to obtain the article.
[0033] In one aspect, the article is a civilian mask or a medical mask, and the combination of the essential oil masterbatch or essential oil microcapsule or essential oil bursting bead with other components of the article includes adding the essential oil masterbatch or essential oil microcapsule or essential oil bursting bead to the civilian mask or the medical mask. Attached Figure Description
[0034] To more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings of the embodiments will be briefly described below. Obviously, the drawings described below only relate to some embodiments of the present disclosure and are not intended to limit the present disclosure.
[0035] Figure 1 shows a comparison of the inhibition rates of various compound essential oils against H1N1, H3N, FluB, hRHV, and RSV according to at least one embodiment of this application.
[0036] Figure 2 shows the minimum inhibitory concentrations of various compound essential oils against a variety of Gram-positive bacteria according to at least one embodiment of this application;
[0037] Figure 3 shows the minimum inhibitory concentrations of various compound essential oils against a variety of Gram-negative bacteria according to at least one embodiment of this application. Detailed Implementation
[0038] For the purposes of the detailed description below, it should be understood that various alternative variations and sequences of steps may be employed in this application unless expressly stated otherwise. Furthermore, except in any operational example or otherwise indicated, all figures representing the amounts of ingredients used, for example, in the specification and claims, should be understood to be modified in all cases by the term “about.” Therefore, unless indicated to the contrary, the numerical parameters set forth in the following specification and appended claims are approximate values varying according to the desired performance to be obtained in this application. At least not in an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be interpreted at least according to the number of significant figures reported and by applying ordinary rounding techniques.
[0039] While the numerical ranges and parameters described in this application are approximate, the values listed in the specific examples are reported as precisely as possible. However, any numerical value inherently contains some error that is necessarily caused by the standard deviation found in their respective test measurements.
[0040] Furthermore, it should be understood that any numerical range described herein is intended to include all subranges falling within it. For example, the range “1 to 10” is intended to include all subranges between the minimum value 1 and the maximum value 10, i.e., a minimum value equal to or greater than 1 and a maximum value equal to or less than 10.
[0041] In this application, unless otherwise expressly stated, the use of the singular includes the plural and the plural includes the singular. Furthermore, in this application, unless otherwise expressly stated, “or” is used to mean “and / or,” even if “and / or” may be explicitly used in certain circumstances. Additionally, in this application, unless otherwise expressly stated, “a” or “an” is used to mean “at least one.” For example, “a” polymer, “a” composition, etc., refer to any one or more of these articles.
[0042] In one embodiment of this application, an antimicrobial essential oil composition is provided. As used herein, the term "antimicrobial" refers to a product having the activity of reducing / killing microorganisms. In the context of this application, "microorganisms" can include bacteria, fungi, viruses, mycoplasma, etc., such as, but not limited to, coronaviruses (e.g., SARS-CoV, MERS-CoV, SARS-CoV-2, etc.), hepatitis viruses (e.g., hepatitis A, B, and C viruses), influenza viruses (e.g., influenza A, B, and avian influenza viruses), Staphylococcus aureus, Klebsiella pneumoniae, Salmonella typhi, Candida albicans, molds, Mycoplasma pneumoniae, etc. In a preferred aspect, the virus in the context of this application can be the novel coronavirus.
[0043] As used herein, the term "plant essential oil" refers to the general term for volatile aromatic substances extracted from natural aromatic plants. Typically, plant essential oils are volatile aromatic substances extracted from the flowers, leaves, roots, seeds, fruits, bark, resins, and heartwood of plants through steam distillation, cold pressing, enfleurage, or solvent extraction. Plant essential oils often possess specific biological activities; in particular, some plant essential oils exhibit good antimicrobial activities, such as antibacterial, antifungal, and / or antiviral activities, and can serve as effective and environmentally friendly antimicrobial agents. Plant essential oils can be classified into single-ingredient and compound essential oils. Compared to single-ingredient essential oils, compound essential oils contain multiple effective essential oil components, and through the synergistic effect of these components, significantly better biological activities, such as antimicrobial activity, can be achieved. Compound essential oils are preferred in this application.
[0044] At least one embodiment of this application provides an antimicrobial essential oil composition comprising:
[0045] (1) Selected from one or more of carvacrol and thymol, the amount of which can be 0.0001-99.99%, preferably 2-80%, more preferably 2-60%, and even more preferably 6-16%;
[0046] (2) Selected from one or more of lemon oil, sweet orange oil, bitter orange peel oil, white lemon oil and grapefruit peel oil, the amount of which can be 0.0001-99.99%, preferably 2-80%, more preferably 2-50%, more preferably 10-50%, and even more preferably 32-38%;
[0047] (3) Selected from one or more of Asian peppermint oil, Asian peppermint oil, peppermint oil and peppermint oil, the amount of which can be 0.0001-99.99%, preferably 2-80%, more preferably 5-40%, and even more preferably 28-35%;
[0048] (4) Selected from one or more of laurel leaf oil and oregano oil, the amount of which may be 0.0001-20%, preferably 2-20%, more preferably 2-18%, more preferably 2-15%, and even more preferably 8-12%;
[0049] (5) Selected from one or more of patchouli oil, sandalwood oil and rosemary oil, the amount of which may be 0.0001-20%, preferably 0.1-18%, more preferably 0.1-5%, and even more preferably 0.3-1%;
[0050] (6) Selected from one or more of geranium oil, pine needle oil, and cypress oil, in an amount of 0.0001-20%, preferably 2-20%, more preferably 2-18%, and even more preferably 3-8%.
[0051] The percentages above are based on the total weight of the composition.
[0052] In one aspect, the antiviral essential oil composition may optionally contain (7) one or more selected from perilla oil, chrysanthemum oil and vitex leaf oil, in an amount of 0.0001-20%, preferably 2-18%, more preferably 2-15%, and even more preferably 8-12%, the percentages being based on the total weight of the composition.
[0053] On the other hand, the antiviral essential oil composition may optionally contain one or more selected from (8) 0.0001-20% honeysuckle oil; (9) 0.0001-20% chuanxiong oil; (10) 0.0001-20% cocklebur oil; and (11) 0.0001-20% forsythia oil, the percentages being based on the total weight of the composition.
[0054] For example, but not limited to, a preferred example of the antimicrobial essential oil composition described in this application may contain: (1) 5% carvacrol and 5% thymol; (2) 35% lemon oil; (3) 30% peppermint oil; (4) 10% bay leaf oil; (5) 0.5% patchouli oil; (6) 5% geranium oil; and (7) 9.5% perilla oil, the percentages being based on the total weight of the composition.
[0055] For example, but not limited to, another preferred example of the antimicrobial essential oil composition described in this application may contain: (1) 0.005% carvacrol and 0.005% thymol; (2) 0.1% lemon oil; (3) 99.58% Asian peppermint oil; (4) 0.005% bay leaf oil; (5) 0.25% patchouli oil; (6) 0.005% geranium oil; and (7) 0.05% perilla oil, the percentages being based on the total weight of the composition.
[0056] For example, but not limited to, another preferred example of the antimicrobial essential oil composition described in this application may comprise: (1) 0.005% carvacrol and 0.005% thymol; (2) 99.5% lemon oil; (3) 0.25% peppermint oil; (4) 0.005% bay leaf oil; (5) 0.18% patchouli oil; (6) 0.005% geranium oil; and (7) 0.05% perilla oil, the percentages being based on the total weight of the composition.
[0057] For example, but not limited to, another preferred example of the antimicrobial essential oil composition described in this application may contain: (1) 51.25% carvacrol; (2) 26.25% thymol; (3) 8.75% lemon oil; (4) 7.5% peppermint oil; (5) 2.5% bay leaf oil; (6) 0.125% patchouli oil; (7) 1.25% geranium oil; and (8) 2.375% perilla oil, the percentages being based on the total weight of the composition.
[0058] For example, but not limited to, another preferred example of the antimicrobial essential oil composition described in this application may include: (1) 25% carvacrol and 25% thymol; (2) 2% lemon oil; (3) 10% peppermint oil; (4) 20% bay leaf oil; (5) 0.5% patchouli oil; (6) 2% geranium oil; (7) 5% honeysuckle oil; (9) 4% ligusticum oil; (10) 0.3% cocklebur oil; and (11) 0.2% forsythia oil.
[0059] The antimicrobial essential oil composition described in this application comprises multiple components that work synergistically to achieve excellent antimicrobial properties. For example, the antimicrobial essential oil composition described in this application can exhibit good killing or inhibitory effects against microorganisms selected from bacteria, fungi, viruses, mycoplasma, or combinations thereof. In one aspect, examples of bacteria described in this application may include one or more of Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Moraxella catarrhalis, Escherichia coli, Shigella dysenteriae, Staphylococcus albus, and Candida albicans. In another aspect, examples of viruses described in this application may include one or more of SARS-CoV-2, influenza virus, rhinovirus, respiratory syncytial virus, enterovirus, adenovirus, herpesvirus, Coxsackievirus, and poliovirus, such as SARS-CoV-2. In yet another aspect, the mycoplasma described in this application may be Mycoplasma pneumoniae.
[0060] For example, when the essential oil composition of this application is used for in vitro disinfection of the novel coronavirus, the killing efficiency after 3 minutes and 30 minutes of treatment can be higher than 75%, for example, higher than 80%, 85%, 90%, 95%, 98%, or even close to 100%. Not wishing to be limited by any theory, the applicant believes that the mechanism by which the essential oil composition kills the novel coronavirus can be at least partially based on the following fact: the novel coronavirus has an envelope structure and is a lipophilic virus, theoretically easily adsorbed and enriched by natural plant essential oils, and thus inactivated. The applicant's research found that after the antiviral plant essential oil of this application comes into contact with and mixes with the original novel coronavirus solution, it can "extract" the novel coronavirus from the solution, thereby rapidly and efficiently inactivating the novel coronavirus. The various essential oil components selected in this application exhibit complementary and additive activity, achieving unexpected synergistic effects compared to single essential oils, resulting in significantly better antimicrobial properties. In addition, the essential oil composition of this application can achieve other beneficial effects, including but not limited to, some components of the composition can block the binding of the novel coronavirus to the ACE2 receptor of respiratory epithelial cells (i.e., achieve a blocking / protective effect); some components can facilitate breathing and improve nasal congestion caused by early viral upper respiratory tract infections or colds (i.e., a soothing effect). Moreover, the essential oil composition of this application is made from natural plant materials, has a fragrant aroma, and has many advantages such as low irritation, low corrosiveness, non-toxicity and harmlessness to the human body, and environmental friendliness.
[0061] At least one embodiment of this application also provides an article comprising an antimicrobial essential oil composition. The article may include articles capable of disinfecting the environment or human body against microorganisms. In one aspect, the article capable of disinfecting the environment or human body described in this application refers to an article that is non-toxic, non-irritating, non-corrosive, environmentally friendly, and capable of reducing or killing harmful microorganisms in the environment or on the human body. It may include, for example, articles capable of reducing or killing microorganisms on one or more of hard surfaces, textiles, skin, mucous membranes, or hair. In the context of this application, the term "hard surface" refers to the surface of an environmental object other than textile surfaces and human body surfaces, including but not limited to commonly used surfaces that are easily accessed in daily life, such as ceilings, walls, floors / tiles, elevators, stairs, handrails, furniture, tableware, and vehicles; the term "textiles" includes but is not limited to clothing, hats, towels, tablecloths, bedding, etc.; the term "skin" refers to the skin of a human or animal; the term "mucous membrane" refers to the oral, ocular, or rectal mucous membranes of a human or animal; and the term "hair" refers to human hair or body hair, or animal hair or feathers. In some examples, products capable of reducing or killing microorganisms on one or more of hard surfaces, textiles, skin, mucous membranes, or hair may include one or more of the following: mask pods, sanitary wipes, air fresheners (such as air gels or air sprays), mouth sprays, personal hygiene products (such as hand sanitizers, shampoos, conditioners, shower gels, etc.), cosmetics, skin care products, air gels, antibacterial sprays, surface cleaners (such as furniture cleaners, floor cleaners, kitchen cleaners, toilet cleaners, etc.), and detergents (such as laundry detergents, dishwashing detergents, etc.).
[0062] Alternatively or optionally, the articles described in this application may also include protective equipment. For example, protective equipment may include one or more selected from everyday clothing (such as underwear, outerwear, or socks), masks (such as civilian masks, medical masks, etc.), protective gloves, and protective clothing, such as beaded masks.
[0063] Alternatively or optionally, the articles described in this application may also include food or health products. For example, food or health products may include one or more of chewing gum, chewing pills, popping beads, gel candies, hard candies, soft candies, beverages, and dietary supplements.
[0064] At least one embodiment of this application also provides a method for preparing the antimicrobial essential oil composition as described above, comprising uniformly mixing all components of the antimicrobial essential oil composition. In one aspect, the mixing is carried out at room temperature and pressure.
[0065] At least one embodiment of this application also provides a method for preparing an article comprising an antimicrobial essential oil composition, comprising uniformly mixing all components of the antimicrobial essential oil composition to form an essential oil masterbatch, essential oil microcapsule, or essential oil bursting bead, and combining the essential oil masterbatch or essential oil microcapsule with other components of the article to obtain the article. For example, this preparation method may include uniformly mixing all components of the antimicrobial essential oil composition to form an essential oil masterbatch, essential oil microcapsule, or essential oil bursting bead; and adding the formed essential oil masterbatch, essential oil microcapsule, or essential oil bursting bead to a mask (such as a civilian mask or a medical mask). During use, the essential oil masterbatch, essential oil microcapsule, or essential oil bursting bead in the mask (after being crushed by pressing) will slowly and continuously release the antiviral essential oil composition, thereby disinfecting pathogenic microorganisms that may be present in the gas (such as air) inhaled or exhaled through the mask.
[0066] The present application will be further explained in detail below with reference to embodiments. However, those skilled in the art should understand that these embodiments are provided for illustrative purposes only and are not intended to limit the present application.
[0067] Example
[0068] The embodiments of this application will be described in detail below with reference to examples. However, those skilled in the art will understand that the following examples are for illustrative purposes only and should not be construed as limiting the scope of this application. Unless otherwise specified, specific conditions in the examples are performed under conventional conditions or conditions recommended by the manufacturer. Reagents or instruments used without specified manufacturers are all commercially available conventional products. Unless otherwise indicated, all quantities listed are described in parts by weight based on total weight. This application should not be construed as being limited to the specific embodiments described.
[0069] Preparation Examples 1-13
[0070] According to the formulations in Tables 1-2 below, the components were mixed at room temperature and pressure to prepare the essential oil compositions of Examples 1-13, wherein Examples 1-7 are the essential oil compositions of this application, and Examples 8-13 are comparative essential oil compositions.
[0071] Table 1.
[0074] [Note]: 1. The numbers in the table above represent percentages based on the total weight of the composition;
[0075] 2. "-" indicates that the corresponding component is not included.
[0076] Table 2.
[0079] [Note]: 1. The numbers in the table above represent percentages based on the total weight of the composition;
[0080] 2. "-" indicates that the corresponding component is not included.
[0081] Test Example 1
[0082] The essential oil composition of Example 1 (labeled as food grade essential oil (FEO)) and the essential oil composition of Example 3 (labeled as cosmetic grade essential oil (CEO)) were prepared respectively.
[0083] The following testing methods were used to test the cytotoxicity and inactivation of SARS-CoV-2 by FEO and CEO.
[0088] The results above demonstrate that the essential oil compositions FEO and CEO of this application exhibit acceptable cytotoxicity and excellent SARS-CoV-2 killing effects.
[0089] Test Example 2
[0090] The effects of the essential oil compositions of the examples and comparative examples against SARS-CoV-2 were evaluated at the cellular level in the following manner.
[0091] Material
[0092] Cells: VeroE6 cells.
[0093] Virus: SARS-CoV-2 (South African variant), titer: TCID 50 =10 -5 / 100μL, using a viral titer of 100 TCID 50 .
[0094] Essential oils: The compound essential oils were diluted to 6 concentrations using cell culture medium via a serial dilution method.
[0095] method
[0096] (I) Antiviral Experiment of Test Drug
[0097] (1) Test drug:
[0098] Table 2: Names, experimental concentrations, and groups of cytotoxic drugs in compound essential oils
[0100] Table 3: Drug Names, Experimental Concentrations, and Groupings in Compound Essential Oil Cytotoxicity Experiments
[0103] (2) Add 100 μL of 1×10⁻⁶ solution to each well of a sterile 96-well culture plate. 5 VeroE6 cells / mL, cultured at 37°C with 5% CO2 for 24 hours;
[0104] (3) 100 TCID was added to the culture plate experimental group and the virus control group. 50 100 μL virus solution per well, 37°C
[0105] 5% CO2 incubator adsorption for 2 hours;
[0106] (4) After 2 hours, discard the cell culture medium in the 96-well culture plate; dilute the test drug to the concentrations shown in Table 1, with 3 replicates for each concentration, and add 100 μL / well of the above drug solution.
[0107] (5) Simultaneously set up cell control, blank control (solvent control), virus control (negative control) and comparative drug control;
[0108] (6) Incubate the cells at 37°C in a 5% CO2 incubator for 3 days;
[0109] (7) Cytopathic effect (CPE) was observed under an optical microscope. The degree of cytopathic effect was recorded according to the following 6-level standard: "-" No cytopathic effect; "±" Less than 10% cytopathic effect; "+" Approximately 25% cytopathic effect; "++" Approximately 50% cytopathic effect; "+++" Approximately 75% of cells showed cytopathic effect; "++++" More than 75% cytopathic effect. The half-maximal effective concentration (IC50) was calculated using the Reed-Muench method or GraphPad Prism 5.0. 50 Criteria for judging efficacy: A concentration that inhibits the virus CPE by 50% is considered an effective concentration.
[0110] (8) Experimental conditions: All the above experimental operations were completed in the BSL-3 laboratory.
[0111] result
[0112] 1. MTS detection of compound essential oil cytotoxicity:
[0113] When VeroE6 cells reached their optimal growth state, they were digested with 0.02% EDTA and 0.5% trypsin. The cell concentration was adjusted to the desired level using growth medium, and the cell culture was added to 96-well cell culture plates at 100 μL / well. The cells were cultured at 37°C in a 5% CO2 incubator until a dense cell monolayer was formed. The compound essential oil was diluted to different concentrations using culture medium: 600 μL / L, 300 μL / L, 150 μL / L, 75 μL / L, 37.5 μL / L, and 18.75 μL / L. Each dilution was run in triplicate, with a normal cell control included. Cells were cultured at 37°C in a 5% CO2 incubator, and cell viability was assessed using the MTS assay. Specific results are shown in Appendix Table 1. None of the compound essential oils at 300 μL / L showed toxicity to VeroE6 cells; therefore, 300 μL / L was selected as the highest experimental concentration for subsequent experiments.
[0114] 2. CPE Observation: 72 hours after viral infection, no CPE was observed in the normal cell control group, while significant CPE was observed in the virus control group. Different essential oil concentrations showed varying inhibitory effects on CPE. The results were recorded by observing cytopathic effects (CPE) and calculating the half-maximal effective concentration (IC50) using the Reed-Muench method or GraphPad Prism 5.0. 50 The specific results are shown in Appendix Table 2. All compound essential oils in each group had antiviral effects, and compared with the comparative example, the examples were significantly better than the comparative example.
[0117] Test Example 3
[0118] The in vitro antiviral efficacy of the essential oil compositions of the examples and comparative examples against influenza virus, rhinovirus, and respiratory syncytial virus was evaluated at the cellular level according to the following method.
[0119] Experimental materials:
[0120] 1. Test Compositions: Compound essential oils 1-10 were prepared according to the formulations listed in Table 4 below, wherein compound essential oil 8 is the essential oil composition of Example 2, compound essential oil 9 is the essential oil composition of Example 1, and compound essential oil 10 is the essential oil composition of Example 3.
[0121] Table 4.
[0123] 2. Cells: Vero-E6 cells.
[0124] 3. Virus:
[0125] Strain name source A / PR / 8 / 34(H1N1)ATCCA / Aichi / 2 / 68(H3N2)ATCCB / Lee / 1940(FluB)ATCC Human rhinovirus (hRHV)ATCC Respiratory syncytial virus (RSV)ATCC
[0126] Experimental methods
[0127] 1. Cell culture and preparation:
[0128] 1.1 Vero-E6 cell resuscitation:
[0129] The cryopreserved cells were rapidly thawed in a 37°C water bath, centrifuged at 800 rpm for 5 minutes, the cryopreservation solution was removed, 5 mL of fresh culture medium (DMEM, 10% FBS) was added, and the cells were transferred to T25 cell culture flasks and cultured in a 37°C CO2 incubator. After 24 hours, cell growth was observed to confirm whether normal growth had resumed.
[0130] 1.2 Cell passage:
[0131] Wash the surface of Vero-E6 cells twice with 5 mL PBS, digest the cells with 1 mL of 0.25% trypsin-EDTA, and place them in an incubator. Once the cells are observed to become rounded and detach, immediately add 4 mL of fresh culture medium to stop the digestion. Centrifuge the digested cells at 800 pm / min for 5 minutes and seed them into new T75 culture flasks at a 1:1 ratio.
[0132] 1.3 Cell seeding:
[0133] Vero-E6 cells in logarithmic growth phase were digested with 3 mL of 0.25% trypsin-EDTA, centrifuged, resuspended, seeded into 96-well plates, and cultured continuously in a 37°C CO2 incubator.
[0134] 2. Vero-E6 cytotoxicity assay
[0135] 2.1 Dilution of essential oils:
[0136] Take 60 μL of the test essential oil and add it to 60 μL of maintenance culture medium. Mix well and then take 100 μL of the mixture for serial 10-fold dilution with maintenance culture medium.
[0137] 2.2 Cytotoxicity assay:
[0138] Approximately 20 hours later, the Vero-E6 cell density reached 90%. The upper layer of culture medium in the 96-well plate was discarded, and the cells were washed twice with PBS. The diluted essential oil solution was added to the 96-well plate, and a cell control group (N, without essential oil, using maintenance culture medium instead) was set up. The cell status was observed visually after 72 hours.
[0139] 3. Virus treatment and cell infection
[0140] 3.1 Mixed treatment of virus and essential oil:
[0141] Add 200 μL of virus solution to each EP tube. For each virus strain, use two EP tubes. Add 200 μL of essential oil or DMEM solution to each of the two EP tubes containing the virus solution, resulting in a total of 400 μL of mixture per EP tube. After mixing, incubate at room temperature for 60 minutes, labeling them as FEO (essential oil and virus solution mixture treated for 60 minutes) and Ctrl (DMEM and virus solution mixture treated for 60 minutes), respectively.
[0142] 3.2 Dilution of the virus essential oil mixture:
[0143] After standing at room temperature for 60 minutes, take 100 μL from each tube and dilute the virus essential oil mixture 10 times with virus diluent. Repeat each group 3 times.
[0144] 3.3 Cell infection:
[0145] In a 96-well plate already seeded with Vero-E6 cells, 100 μL of essential oil-virus or DMEM-virus dilution buffer was added to each well, with six replicates for each dilution. Virus positive control wells and normal cell wells were also included, and the plates were incubated at 37°C in a CO2 incubator.
[0146] 3.4 Observation of cytopathic effects:
[0147] After 72 hours, the cytopathic effect was observed under a microscope, and the TCID of each group was calculated according to the Reed-Muench formula. 50 The values were compared, and the inhibition rate of essential oils against viruses was also analyzed.
[0148] Distance ratio = (Percentage of lesions with a rate higher than 50% - 50%) / (Percentage of lesions with a rate higher than 50% - Percentage of lesions with a rate lower than 50%);
[0149] lgTCID50 = Distance ratio × Logarithm of dilution factor + Logarithm of dilution with a lesion rate higher than 50%
[0150] Inhibition rate = (Virus titer in control wells - Virus titer in experimental wells) / Virus titer in control wells × 100%
[0151] 3.5 Experimental conditions:
[0152] All the above experimental procedures were performed in the BSL-3 laboratory.
[0153] Experimental results
[0154] 1. Cytotoxicity results of compound essential oils: After 72 hours, the essential oils showed cytotoxicity at a rate of 10% (visually observed by the naked eye). - 1 -10 -4 After dilution, the cells in the experimental wells died; the essential oil was used as 10 -5 The diluted cells treated with the oil showed normal morphology and no significant difference compared to the control group. Therefore, the maximum non-toxic concentration of the essential oil to Vero-E6 cells, as observed by the naked eye, was 10 times that of the undiluted essential oil solution. -5 dilution.
[0155] 2. Results of the antiviral effect of essential oils: 72 hours after viral infection, no CPE was observed in the normal cell control group, while significant CPE was observed in the virus control group. Different essential oil concentration groups showed different inhibitory effects on CPE. The virus inhibition rate of each group of essential oils was calculated based on the virus titer of each group. The specific results are shown in Tables 5-9. The summary results of the virus inhibition rate of compound essential oils are shown in Table 10 and Figure 1. The results show that all compound essential oils have certain antiviral effects. Compound essential oils 9, 10, and 1 have comparable effects, are better than 7 and 8, better than 3 and 6, and significantly better than 2, 4, and 5.
[0156] Table 5. Inhibitory effect of compound essential oils on H1N2
[0158] Table 6. Inhibitory effect of compound essential oils on H3N2
[0161] Table 7. Inhibitory effect of compound essential oils on FluB
[0163] Table 8. Inhibitory effect of compound essential oils on hRHV
[0166] Table 9. Inhibitory effect of compound essential oils on RSV
[0168] Table 10. Comparison of inhibition rates of compound essential oils on H1N1, H3N, FluB, hRHV, and RSV
[0169] Essential oil formula H1N1H3N2FluBhRHVRSV1 98.68±12.58 95.68±12.58 99.12±3.80 95.28±3.39 98.07±3.65 258.72±7.41 58.72±7.41 59.66±6.64 54.30±5.93 53.15±6.64 383.12±5 .4873.12±5.4888.84±12.1971.09±10.8776.11±11.9446.00±6.4556.00±6.4561.55±11.4852.51±5.9646.50±6.52564.84±6.0864.84±6.0863.66±6.6855.99±10 .2450.31±11.2684.68±5.4384.68±5.4384.80±7.2176.72±6.4378.24±9.97785.65±10.4285.65±10.4286.05±3.9074.27±3.4883.58±9.61879.12±3.3279.12±3 .3292.72±5.6278.25±5.0183.88±8.19999.83±1.3598.83±1.3598.67±4.1698.49±4.2897.98±6.671098.72±5.7996.72±5.7997.97±2.1196.13±2.0497.45±5.49
[0170] Test Example 4
[0171] The in vitro antibacterial activity of the essential oil compositions of the examples and comparative examples against a variety of Gram-positive and Gram-negative bacteria was evaluated at the cellular level according to the following method.
[0172] Experimental materials:
[0173] 1. Test composition: The test composition used in this test example is the same as the compound essential oils 1-10 used in test example 3, wherein compound essential oil 8 is the essential oil composition of example 2, compound essential oil 9 is the essential oil composition of example 1, and compound essential oil 10 is the essential oil composition of example 3.
[0174] 2. Standard strains:
[0175] Standard strains were derived from: *Dendrobium pneumoniae* (strain number 31001), *Staphylococcus aureus* (strain number 26112), *Staphylococcus epidermidis* (strain number 26487), *Moraxella catarrhalis* (strain number 29103), *Escherichia coli* (strain number 44155), and *Shigella dysenteriae* (strain number 51592).
[0176] 3. Culture media: Ordinary broth medium, ordinary agar medium and serum agar medium were all prepared according to conventional methods.
[0177] Experimental methods
[0178] Three standard Gram-positive bacteria (Deptococcus pneumoniae, Staphylococcus aureus, and Staphylococcus epidermidis) and three standard Gram-negative bacteria (Morphococcus catarrhalis, Escherichia coli, and Shigella dysenteriae) were selected, and the in vitro inhibitory effect of the compound essential oil on the standard strains was observed using the test tube method.
[0179] (1) Essential oil dilution: Dilute 1ml of the original essential oil solution by 5 times to obtain an essential oil concentration of 200μL / ml. Then dilute it according to the ratio dilution method to obtain a total of 9 concentrations of 200, 100, 50, 25, 12.5, 6.25, 3.13, 1.56 and 0.78μL / ml.
[0180] (2) Preparation of bacterial culture: Take cultures of Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Moraxella catarrhalis, Escherichia coli, and Shigella dysenteriae that have been cultured for 18 hours, and dilute them to pH 7.0 sodium chloride-peptone buffer to a concentration of 10. -7 -10 -5 The number of colonies added.
[0181] (3) Experimental Method: The dried antimicrobial susceptibility test discs containing 1000 CFU of bacterial solution were soaked in eight different concentrations of compound essential oils for 1 hour, and then incubated in 10 ml of TSB at 37°C for 48 hours. The TSB was observed to determine if it became turbid. Simultaneously, the discs were inoculated onto isolation agar plates for each strain and incubated at 37°C for 24 hours to observe for colony growth. A positive control without essential oil solution and a negative control with essential oil but without bacterial strain were also set up, with each control repeated three times. The lowest essential oil concentration at which no bacterial growth was observed was taken as the minimum inhibitory concentration (MIC) for the strain.
[0182] Experimental results
[0183] Under the conditions of this experiment, the compound essential oils showed varying degrees of inhibitory effects against common Gram-positive bacteria (Deptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis) and Gram-negative bacteria (Morphococcus catarrhalis, Escherichia coli, Shigella dysenteriae). As shown in Table 11, Figure 2, and Figure 3, the minimum inhibitory concentrations (MICs) of Examples 9, 10, and 1 were comparable in efficacy, superior to Examples 3, 6, 7, and 8, and significantly superior to Examples 2, 4, and 5.
[0184] Table 11. Minimum inhibitory concentration (MIC, μL / ml) of compound essential oils against standard bacterial strains in vitro
[0187] Test Example 5
[0188] According to the method of simulating field test of air disinfection effect in the 2002 edition of "Disinfection Technical Specifications" - 2.1.3.4, the air disinfection effect of the essential oil composition of Example 1 (marked as food grade essential oil (FEO)) against Staphylococcus aureus was tested.
[0189] Measure 200 mL of FEO and add it to the nebulizer. After nebulizing at the highest setting for 1 hour, sample the air using a BY-300 air microbial sampler with a suction rate of 28.3 L / min. The sampling time for the control group was 30 s, and the sampling time for the experimental group was 5 min. The experimental chamber size was 20 m². 3 The results of the kill rate experiment were processed to eliminate the influence of factors such as the natural death of microorganisms in the air. The results are shown in Table 12 below.
[0190] Table 12.
[0192] The results above demonstrate that the essential oil composition of this application has a good disinfection effect against Staphylococcus aureus in the air.
[0193] Test Example 6
[0194] Referring to the virus inactivation test method in Section 2.1.1.10.7 of the 2002 edition of the "Disinfection Technical Specifications," the virus inactivation effect of the essential oil composition of Example 1 (labeled as food-grade essential oil (FEO)) against enterovirus 71, adenovirus, herpesvirus, Coxsackievirus, influenza A virus H1N1, and poliovirus was tested. The results showed:
[0195] - After treating enterovirus 71 (ATCC VR-1432, host name: Vero cells) with FEO stock solution for 30 min, the average inactivation log (KL) was 1.36, and the virus inactivation rate was 95.69%.
[0196] - After treating human herpesvirus A5C strain (ATCC VR-2019, host name: Vero cells) with FEO stock solution for 30 min, the average inactivation log (KL) was >4.37, and the virus inactivation rate was >99.99%.
[0197] - After treating adenovirus type 3 (ATCC VR-3, host name: A454 cells) with FEO stock solution for 30 min, the average inactivation log number (KL) was 1.61, and the virus inactivation rate was 97.56%.
[0198] - After treating Coxsackievirus A21 (ATCC VR-850, host name: Vero cells) with FEO stock solution for 30 min, the average inactivation log (KL) was 1.41, and the virus inactivation rate was 95.97%.
[0199] - After treating influenza A virus H1N1:A / PR / 8 / 34 (ATCC VR-1469, host name: MDCK cells) with FEO stock solution for 30 min, the average inactivation log (KL) was >4.37, and the virus inactivation rate was >99.99%.
[0200] - After treating the poliovirus type I vaccine strain (host name: Vero cells) with FEO stock solution for 30 min, the average inactivation log (KL) was 1.24, and the virus inactivation rate was 94.23%.
[0201] - The negative control group cells grew well, and the experimental results met all the evaluation criteria.
[0202] As can be seen from the above results, the essential oil composition of this application has a good virus inactivation effect against enterovirus 71, adenovirus, herpesvirus, Coxsackievirus, influenza A virus H1N1, and poliovirus.
[0203] Test Example 7
[0204] Referring to the antibacterial rate testing method in Section 2.1.11.3 of the 2002 edition of the "Disinfection Technical Specifications," the antibacterial rate of the essential oil composition (labeled as food-grade essential oil (FEO)) in Example 1 against Escherichia coli, Staphylococcus aureus, and Candida albicans was tested. The results showed that after treatment with undiluted FEO solution for 2 minutes, the antibacterial rate for all three bacteria was >99.9%, meeting the requirements of Section 2.1.11.3 of the 2002 edition of the "Disinfection Technical Specifications."
[0205] The results above show that the essential oil composition of this application has good antibacterial effects against Escherichia coli, Staphylococcus aureus, and Candida albicans.
[0206] Test Example 8
[0207] Based on the mycoplasma culture method and the detection methods in Sections 2.1.1.7 and 2.1.1.9 of the 2002 edition of the "Disinfection Technical Specifications", the essential oil composition of Example 1 (labeled as food-grade essential oil (FEO)) was tested for mycoplasma growth inhibition. The results showed that under the specified experimental conditions, after treating Mycoplasma pneumoniae (ATCC 15531) with undiluted FEO solution at 25°C for 30 min, the logarithmic value of the viable bacteria concentration decreased by >3, and the kill rate was >99%, indicating a killing effect on Mycoplasma pneumoniae.
[0208] The results above show that the essential oil composition of this application has a good killing effect against Mycoplasma pneumoniae.
Claims
1. An antimicrobial essential oil composition, wherein, based on the total weight of the composition, the antimicrobial essential oil composition comprises: (1) 0.0001-80% selected from one or more of carvacrol and thymol; (2) 0.0001-99.9% of the oil is selected from one or more of lemon oil, sweet orange oil, bitter orange peel oil, white lemon oil and grapefruit peel oil; (3) 0.0001-99.9% of the oil is selected from one or more of the following: Asian peppermint oil, Asian peppermint oil, peppermint oil and peppermint oil; (4) 0.0001-20% selected from one or more of laurel leaf oil and oregano oil; (5) 0.0001-20% of one or more of patchouli oil, sandalwood oil and rosemary oil; (6) 0.0001-20% of one or more selected from geranium oil, pine needle oil, and cypress oil; and (7) Optionally, 0.0001-20% is selected from one or more of perilla oil, Hangzhou white chrysanthemum oil and Vitex leaf oil.
2. The antimicrobial essential oil composition of claim 1, wherein, based on the total weight of the composition, the antimicrobial essential oil composition comprises: (1) 2-80% is selected from one or more of carvacrol and thymol; (2) 2-50% is selected from one or more of lemon oil, sweet orange oil, bitter orange peel oil, white lemon oil and grapefruit peel oil; (3) 5-40% is selected from one or more of Asian peppermint oil, Asian peppermint oil, peppermint oil and peppermint oil; (4) 2-20% selected from one or more of laurel leaf oil and oregano oil; (5) 0.1-5% of one or more of patchouli oil, sandalwood oil and rosemary oil; (6) 2-20% selected from one or more of geranium oil, pine needle oil, and cypress oil; and (7)Optionally, 2-15% is selected from one or more of perilla oil, Hangzhou white chrysanthemum oil and Vitex leaf oil.
3. The antimicrobial essential oil composition of claim 1 or 2, wherein, based on the total weight of the composition, the antimicrobial essential oil composition optionally comprises one or more components selected from the group consisting of: (8) 0.0001-20% honeysuckle oil; (9) 0.0001-20% Ligusticum chuanxiong oil; (10) 0.0001-20% Xanthium sibiricum oil; and (11) 0.0001-20% Forsythia oil.
4. The antimicrobial essential oil composition of any one of claims 1-3, wherein, based on the total weight of the composition, the antimicrobial essential oil composition comprises: (1) 5% carvacrol and 5% thymol; (2) 35% lemon oil; (3) 30% Asian peppermint oil; (4) 10% laurel leaf oil; (5) 0.5% patchouli oil; (6) 5% geranium oil; and (7) 9.5% perilla oil.
5. The antimicrobial essential oil composition of any one of claims 1-3, wherein, based on the total weight of the composition, the antimicrobial essential oil composition comprises: (1) 0.005% carvacrol and 0.005% thymol; (2) 0.1% lemon oil; (3) 99.58% Asian peppermint oil; (4) 0.005% laurel leaf oil; (5) 0.25% patchouli oil; (6) 0.005% geranium oil; and (7) 0.05% perilla oil.
6. The antimicrobial essential oil composition of any one of claims 1-3, wherein, based on the total weight of the composition, the antimicrobial essential oil composition comprises: (1) 0.005% carvacrol and 0.005% thymol; (2) 99.5% lemon oil; (3) 0.25% Asian peppermint oil; (4) 0.005% laurel leaf oil; (5) 0.18% patchouli oil; (6) 0.005% geranium oil; and (7) 0.05% perilla oil.
7. The antimicrobial essential oil composition of claim 1, wherein, based on the total weight of the composition, the antimicrobial essential oil composition comprises: (1) 51.25% carvacrol; (2) 26.25% thymol; (3) 8.75% lemon oil; (4) 7.5% Asian peppermint oil; (5) 2.5% laurel leaf oil; (6) 0.125% patchouli oil; (7) 1.25% geranium oil; and (8) 2.375% perilla oil.
8. The antimicrobial essential oil composition of any one of claims 1-3, wherein, based on the total weight of the composition, the antimicrobial essential oil composition comprises: (1) 25% carvacrol and 25% thymol; (2) 2% lemon oil; (3) 10% Asian peppermint oil; (4) 20% laurel leaf oil; (5) 0.5% patchouli oil; (6) 2% geranium oil; (7) 5% honeysuckle oil; (9) 4% Ligusticum chuanxiong oil; (10) 0.3% Xanthium sibiricum oil; and (11) 0.2% Forsythia oil.
9. The antimicrobial essential oil composition according to any one of claims 1-8, wherein, The microorganisms are selected from bacteria, fungi, viruses, mycoplasma, and combinations thereof.
10. The antimicrobial essential oil composition according to any one of claims 1-9, wherein, The microorganisms mentioned are one or more of the following: SARS-CoV-2, influenza virus, rhinovirus, respiratory syncytial virus, enterovirus, adenovirus, herpesvirus, Coxsackievirus, and poliovirus.
11. The antimicrobial essential oil composition of claim 10, wherein, The microorganism in question is the novel coronavirus.
12. The antimicrobial essential oil composition according to any one of claims 1-9, wherein, The microorganisms mentioned are one or more of the following: Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Moraxella catarrhalis, Escherichia coli, Shigella dysenteriae, Staphylococcus albus, and Candida albicans.
13. The antimicrobial essential oil composition according to any one of claims 1-9, wherein, The microorganism in question is Mycoplasma pneumoniae.
14. An article comprising the antimicrobial essential oil composition of any one of claims 1-13.
15. The article of claim 14, wherein, The articles include those capable of reducing or killing microorganisms on one or more of hard surfaces, textiles, skin, mucous membranes, or hair.
16. The article of claim 14 or 15, wherein, The product is selected from one or more of the following: mask capsules, sanitary wipes, air fresheners, oral sprays, hand sanitizers, shampoos, conditioners, shower gels, cosmetics, skin care products, air gels, antibacterial skin sprays, surface cleaners, and detergents.
17. The article of claim 14, wherein, The product in question is a protective item.
18. The article of claim 14 or 17, wherein, The product is selected from one or more of the following: civilian masks, medical masks, protective gloves, and protective clothing.
19. The article of any one of claims 14, 17 and 18, wherein, The product in question is a beaded face mask.
20. The article of claim 14, wherein, The product in question is a food or health product.
21. The article of claim 14 or 20, wherein, The product is selected from one or more of chewing gum, chewing pills, popping beads, gel candy, hard candy, beverages, and dietary supplements.
22. A method for preparing the article of any one of claims 14-21, comprising: All components of the antimicrobial essential oil composition are uniformly mixed to form essential oil masterbatches, essential oil microcapsules, or essential oil burst beads. The essential oil masterbatch, essential oil microcapsule, or essential oil bursting bead is combined with other components of the product to obtain the product.
23. The method of claim 22, wherein, The product in question is a civilian-use mask or a medical mask. The combination of the essential oil masterbatch, essential oil microcapsule, or essential oil bursting bead with other components of the product includes adding the essential oil masterbatch, essential oil microcapsule, or essential oil bursting bead to the civilian mask or the medical mask.
